Tech Company Financing Transactions
Onchilles Pharma Funding Round
LYZZ Capital and The University of Chicago participated in a $7 million Series A funding round for Onchilles Pharma. The round was announced on 6/11/2021.
Transaction Overview
Company Name
Announced On
6/11/2021
Transaction Type
Venture Equity
Amount
$7,000,000
Round
Series A
Investors
LYZZ Capital (Court Turner)
Proceeds Purpose
The proceeds of the financing will be used to develop first-in-class therapeutics to activate a novel pathway of the innate immune system with potential for universal anti-cancer activity, independent of genetic mutation.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
9880 Campus Point Dr. 420
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Onchilles Pharma was founded on breakthrough research that was the first to describe that human neutrophils release a major anticancer protein, called ELANE, that broadly and selectively activates cell death pathways in cancer cells. This fundamental pathway of the innate immune system has the potential for universal anti-cancer activity, independent of genetic mutation.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Court Turner
Co-Founder
Lev Becker
Browse more venture capital transactions:
Prev: 6/11/2021: Transcarent venture capital transaction
Next: 6/14/2021: RudderStack venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs